JP5355086B2 - 腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法 - Google Patents

腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法 Download PDF

Info

Publication number
JP5355086B2
JP5355086B2 JP2008527374A JP2008527374A JP5355086B2 JP 5355086 B2 JP5355086 B2 JP 5355086B2 JP 2008527374 A JP2008527374 A JP 2008527374A JP 2008527374 A JP2008527374 A JP 2008527374A JP 5355086 B2 JP5355086 B2 JP 5355086B2
Authority
JP
Japan
Prior art keywords
mmp
rcc
pro
measured
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008527374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506307A (ja
Inventor
ブルーノ・ダルブール
ゲアネ・サーキシアン
Original Assignee
セザンヌ・エス・アー・エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セザンヌ・エス・アー・エス filed Critical セザンヌ・エス・アー・エス
Publication of JP2009506307A publication Critical patent/JP2009506307A/ja
Application granted granted Critical
Publication of JP5355086B2 publication Critical patent/JP5355086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2008527374A 2005-08-26 2006-08-21 腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法 Active JP5355086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05291783.8 2005-08-26
EP05291783A EP1757940A1 (de) 2005-08-26 2005-08-26 In vitro Methode zur Diagnose und zum Monitoring von Nierenzellkarzinom unter Verwendung von MMP-7 als humoraler Biomarker für Nierenzellkarzinom
PCT/EP2006/008212 WO2007022940A1 (en) 2005-08-26 2006-08-21 In vitro method for diagnosing and monitoring renal cell carcinoma (rcc) using mmp-7 as humoral biomarker for rcc

Publications (2)

Publication Number Publication Date
JP2009506307A JP2009506307A (ja) 2009-02-12
JP5355086B2 true JP5355086B2 (ja) 2013-11-27

Family

ID=35124371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527374A Active JP5355086B2 (ja) 2005-08-26 2006-08-21 腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法

Country Status (5)

Country Link
US (1) US7981621B2 (de)
EP (2) EP1757940A1 (de)
JP (1) JP5355086B2 (de)
ES (1) ES2399443T3 (de)
WO (1) WO2007022940A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US11150250B2 (en) * 2008-08-28 2021-10-19 Astute Medical, Inc. Methods for diagnosing acute kidney injury or renal failure
EP2813848A3 (de) * 2008-08-29 2015-03-11 Astute Medical, Inc. Verfahren und Zusammensetzungen zur Diagnose und Prognose von Nierenläsion und Niereninsuffizienz
CN103760359B (zh) 2008-10-21 2017-01-11 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ619918A (en) * 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0922021A2 (pt) 2008-11-10 2019-09-24 Astute Medical Inc método para avaliar a condição renal em um indivíduo, e, uso de um ou mais marcadores de lesão renal
US20110229915A1 (en) * 2008-11-22 2011-09-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011017654A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100227335A1 (en) * 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2011037045A1 (ja) 2009-09-25 2011-03-31 国立大学法人北海道大学 腎細胞癌の判定法
CN102725635B (zh) 2009-11-07 2015-05-20 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2818138T3 (es) * 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
KR101940014B1 (ko) 2010-02-05 2019-01-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
AU2011220413B2 (en) 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5808349B2 (ja) * 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ703055A (en) 2010-06-23 2016-07-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105823887B (zh) * 2011-01-28 2018-06-12 西瑞斯实验室有限公司 用于检测肠和血脑屏障通透性的方法及其测试材料
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
ES2926197T3 (es) 2013-01-17 2022-10-24 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
RU2015144149A (ru) * 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф
JP2016540759A (ja) 2013-12-03 2016-12-28 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
CA3026502A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2949467B2 (ja) 1995-02-16 1999-09-13 富士薬品工業株式会社 免疫学的測定法によるヒトプロマトリックスメタロプロテアーゼ７の定量
JPH10287700A (ja) 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン（ｍｍｐ−７）に対する抗体及びそれを用いた免疫学的測定法
CZ20032787A3 (en) 2001-04-03 2004-03-17 Merck Patent Gmbh Renal cell carcinoma tumor markers
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
AU2003231853A1 (en) 2002-05-22 2003-12-12 The Cleveland Clinic Foundation Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
EP1709421B1 (de) * 2004-01-09 2017-08-02 Children's Medical Center Corporation Verfahren zur diagnose und prognose von krebserkrankungen epithelialer genese

Also Published As

Publication number Publication date
US7981621B2 (en) 2011-07-19
JP2009506307A (ja) 2009-02-12
WO2007022940A1 (en) 2007-03-01
EP1757940A1 (de) 2007-02-28
EP1920256B1 (de) 2012-11-14
ES2399443T3 (es) 2013-04-01
US20080254483A1 (en) 2008-10-16
EP1920256A1 (de) 2008-05-14

Similar Documents

Publication Publication Date Title
JP5355086B2 (ja) 腎細胞癌（ＲＣＣ）に対する体液性バイオマーカーとしてＭＭＰ−７を使用する、ＲＣＣを診断及びモニターするためのｉｎｖｉｔｒｏ方法
US20190361028A1 (en) Free ngal as a biomarker for cancer
US20180120319A1 (en) Methods for diagnosis and prognosis of epithelial cancers
JP5563988B2 (ja) 癌のマーカーとしてのセプラーゼ
AU2005207318B2 (en) Methods for diagnosis and prognosis of cancers of epithelial origin
JP5155309B2 (ja) 患者の循環液中のＭＭＰ−７の測定を利用した転移した膀胱ガンを診断およびモニターするためのｉｎｖｉｔｒｏ方法
AU2006216925A1 (en) ADAMTS-7 as a biomarker for cancers of epithelial origin
CA3016668A1 (en) Chromogranin a as a marker for bladder cancer
JP2005527828A (ja) 前立腺癌検出改善のための試料中の非複合体型前立腺特異抗原の分析方法
WO2011126482A1 (en) Immunoassay for the diagnosis of prostate cancer
WO2009017475A1 (en) Methods for diagnosis and prognosis of epithelial cancers
Swellam et al. Clinical implications of proteolytic activity imbalance in breast cancer diagnosis
Johnson et al. Selecting Severe Cases of Acute Pancreatitis for Trials and for Treatment: Enzymes and Activation Peptides

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130827

R150 Certificate of patent or registration of utility model

Ref document number: 5355086

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250